Remibrutinib manufacturers
- Remibrutinib
-
-
2026-08-18
- CAS:1787294-07-8
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- Remibrutinib
-
- $98.00
-
2026-07-27
- CAS:1787294-07-8
- Purity: 99.74%
- Supply Ability: 10g
- Remibrutinib
-
-
2026-07-24
- CAS:1787294-07-8
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1000kgs
|
| | Remibrutinib Basic information |
| Product Name: | Remibrutinib | | Synonyms: | REMIBRUTINIB;N-(3-{5-[2-(Acryloyl-methyl-amino)-ethoxy]-6-amino-pyrimidin-4-yl}-5-fluoro-2-methyl-phenyl)-4-cyclopropyl-2-fluoro-benzamide;Benzamide, N-[3-[6-amino-5-[2-[methyl(1-oxo-2-propen-1-yl)amino]ethoxy]-4-pyrimidinyl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluoro-;Remibrutinib (LOU064);Btk,Inhibitor,inhibit,Remibrutinib,Bruton tyrosine kinase;N-[3-[6-Amino-5-[2-[methyl(1-oxo-2-propen-1-yl)amino]ethoxy]-4-pyrimidinyl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide;Remibrutinib, 10 mM in DMSO;Lou064/Remibrutinib | | CAS: | 1787294-07-8 | | MF: | C27H27F2N5O3 | | MW: | 507.53 | | EINECS: | | | Product Categories: | chemical | | Mol File: | 1787294-07-8.mol |  |
| | Remibrutinib Chemical Properties |
| Boiling point | 634.8±55.0 °C(Predicted) | | density | 1.332±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 125 mg/mL (246.29 mM) | | form | Solid | | pka | 11.67±0.70(Predicted) | | color | White to off-white | | InChIKey | CUABMPOJOBCXJI-UHFFFAOYSA-N | | SMILES | C(NC1=CC(F)=CC(C2C(OCCN(C)C(=O)C=C)=C(N)N=CN=2)=C1C)(=O)C1=CC=C(C2CC2)C=C1F |
| | Remibrutinib Usage And Synthesis |
| Description | Remibrutinib, is a potent and orally active bruton tyrosine kinase (BTK) inhibitor with an IC50 value of 1 nM. Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood. Remibrutinib has the potential for Chronic urticaria (CU) treatment. | | Chemical Properties | White to off-white Solid | | Uses | Remibrutinib, is a potent and orally active bruton tyrosine kinase (BTK) inhibitor with an IC50 value of 1 nM. Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood[1]. Remibrutinib has the potential for Chronic urticaria (CU) treatment[2]. | | References | [1] Daniela Angst, et al. Novel amino pyrimidine derivatives. Patent WO2015079417A1.
[2] Kolkhir P, et al. New treatments for chronic urticaria. Ann Allergy Asthma Immunol. 2019 Aug 23. DOI:10.1016/j.anai.2019.08.014 |
| | Remibrutinib Preparation Products And Raw materials |
|